IVVD Share Price Performance
US$1.30
0.72 (124.49%)
87.0% undervalued intrinsic discount
US$10.00
Fair Value
Price US$1.30
AnalystConsensusTarget US$10.00
AnalystLowTarget US$1.00
AnalystHighTarget US$5.00
Fair ValueUS$10.00
Share Pricen/a
Invivyd, Inc. Stock Price
- 4 Narratives written by author
- 0 Comments on narratives written by author
- 92 Fair Values set on narratives written by author
IVVD Community Narratives
AN
Fair Value US$10 86.7% undervalued intrinsic discount
Analysts Hold Invivyd Price Target Steady as FDA Progress and Valuation Metrics Update
0users have liked this narrative
0users have commented on this narrative
39users have followed this narrative
AN
Fair Value US$1 33.0% overvalued intrinsic discount
Regulatory Risks And Competition Will Impede Gains But Yield Promise
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$5 73.4% undervalued intrinsic discount
Rapid Antibody Advances Will Leverage Secular Pandemic Trends
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Analysts Hold Invivyd Price Target Steady as FDA Progress and Valuation Metrics Update
Key Takeaways Expansion of a skilled commercial team and new therapeutic programs positions Invivyd for broader market adoption, revenue growth, and reduced product concentration risk. Financial discipline and evolving regulatory support enhance sustainability, lower risk, and may fast-track product approvals and recurring revenue opportunities.Read more
593
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
39users have followed this narrative
AN
US$10
86.7% undervalued intrinsic discount
Fair Value
Profit Margin
5.64%
Future PE
281.74x
Price in 2029
US$12.26
Regulatory Risks And Competition Will Impede Gains But Yield Promise
Key Takeaways Heavy reliance on emergency authorizations, regulatory uncertainties, and a narrow late-stage pipeline threaten Invivyd's long-term revenue stability and growth prospects. Heightened pricing pressures, high R&D costs, and formidable competition may erode profitability despite strong product demand and innovative advances in antibody engineering.Read more
33
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$1
33.0% overvalued intrinsic discount
Fair Value
Profit Margin
7.36%
Future PE
9.44x
Price in 2028
US$1.97
Rapid Antibody Advances Will Leverage Secular Pandemic Trends
Key Takeaways Invivyd's COVID-19 and next-generation antibody products are primed for durable, expanding revenue streams, potentially outpacing market expectations through breakthrough clinical benefits and guideline inclusion. The company's diversified pipeline, pandemic readiness focus, and operational efficiency position it for higher growth, stronger margins, and sustained earnings in a shifting healthcare landscape.Read more
29
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$5
73.4% undervalued intrinsic discount
Fair Value
Profit Margin
48.47%
Future PE
5.61x
Price in 2028
US$9.85
Trending Discussion
Recently Updated Narratives
AN
IVVD: Phase 3 COVID Prevention And Long COVID Trial Will Drive Upside
Fair Value: US$10 86.7% undervalued intrinsic discount
39 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Regulatory Risks And Competition Will Impede Gains But Yield Promise
Fair Value: US$1 33.0% overvalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Rapid Antibody Advances Will Leverage Secular Pandemic Trends
Fair Value: US$5 73.4% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Invivyd, Inc. Key Details
About IVVD
- Founded
- 2020
- Employees
- 122
- CEO
- WebsiteView website
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in pre-clinical trial stage for the prevention and treatment of respiratory syncytial virus and measles in neonates, infants, and children. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in New Haven, Connecticut.
